Additionally, the 36-month beta value for SLS is 2.42. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for SLS is 69.73M and currently, short sellers hold a 10.69% ratio of that float. The average trading volume of SLS on December 26, 2024 was 989.05K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SLS) stock’s latest price update
SELLAS Life Sciences Group Inc (NASDAQ: SLS)’s stock price has gone rise by 3.94 in comparison to its previous close of 0.93, however, the company has experienced a 14.88% increase in its stock price over the last five trading days. globenewswire.com reported 2024-12-10 that – Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – – REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 – – Company to Host Webcast Call Today at 9:00 am ET NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the pre-specified threshold of 60 events (deaths) has been reached in its ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), triggering the interim analysis to be conducted by the Independent Data Monitoring Committee (IDMC). The IDMC will conduct a thorough review of the current REGAL data, and the interim analysis will provide an assessment of efficacy, futility as well as safety of GPS.
SLS’s Market Performance
SELLAS Life Sciences Group Inc (SLS) has seen a 14.88% rise in stock performance for the week, with a -17.42% decline in the past month and a -23.93% plunge in the past quarter. The volatility ratio for the week is 8.78%, and the volatility levels for the past 30 days are at 10.47% for SLS. The simple moving average for the last 20 days is -3.30% for SLS’s stock, with a simple moving average of -21.90% for the last 200 days.
Analysts’ Opinion of SLS
Many brokerage firms have already submitted their reports for SLS stocks, with Cantor Fitzgerald repeating the rating for SLS by listing it as a “Overweight.” The predicted price for SLS in the upcoming period, according to Cantor Fitzgerald is $18 based on the research report published on July 21, 2021 of the previous year 2021.
H.C. Wainwright gave a rating of “Buy” to SLS, setting the target price at $11 in the report published on April 02nd of the previous year.
SLS Trading at -14.49% from the 50-Day Moving Average
After a stumble in the market that brought SLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.83% of loss for the given period.
Volatility was left at 10.47%, however, over the last 30 days, the volatility rate increased by 8.78%, as shares sank -20.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.83% lower at present.
During the last 5 trading sessions, SLS rose by +12.97%, which changed the moving average for the period of 200-days by -31.15% in comparison to the 20-day moving average, which settled at $0.9983. In addition, SELLAS Life Sciences Group Inc saw -8.85% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SLS
The total capital return value is set at -2.06. Equity return is now at value -535.10, with -186.64 for asset returns.
Currently, EBITDA for the company is 0.53 million with net debt to EBITDA at 1.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.26.
Conclusion
In conclusion, SELLAS Life Sciences Group Inc (SLS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
